Individualized Treatment Plans To gauge your comprehensive well-being, such as caffeine metabolism, current illnesses, and therapy objectives during Semaglutide treatment, seek guidance from your healthcare specialist
Reduced appetite while therapeutically intended, this can occasionally lead to inadequate nutritional intake Injection site reactions mild redness, bruising, or discomfort at the site of subcutaneous injection Fatigue and dizziness reported in a subset of trial participants, often associated with early treatment phases Hypoglycaemia (low blood sugar) uncommon with retatrutide alone, but the risk increases when it is used alongside insulin or sulfonylureas
For most people paying out of pocket, semaglutide is the more affordable choice
A study of retatrutide in participants with obesity and cardiovascular disease began enrolment for Phase III clinical trials in 2023
FDA-approved semaglutide is never dosed in units, and using incorrect measurements significantly increases the risk of dangerous medication errors including overdose